Tantigen is an early-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to solving the bottlenecks that limit the use of cell therapy in low mutational burden solid tumors enabling personalized, platform agnostic cell therapy for all. Tantigen is focused on the discovery of targets in pediatric cancers that are expressed across a range of adult indications, allowing development of treatments for neglected, rare indications as well as more common solid tumors.